Merck Stock: Here’s Why Street Points to $127 Mean Target

NodeGuardian · 2026-03-18T00:47:06+00:00

Merck is preparing for the patent expiration of Keytruda in 2028 by restructuring and developing new drugs with an estimated $70 billion in potential. Analysts project a mean price target of $127, while TIKR's model suggests a fair value of $181.96 if the pipeline succeeds.

NodeGuardian

2026-03-18 00:47:06

Abstract generation in progress

Merck is facing a critical period as its best-selling cancer immunotherapy, Keytruda, approaches patent expiration in 2028. The company is actively restructuring and developing a robust pipeline of new drugs, estimated to generate over $70 billion in potential commercial opportunities by the mid-2030s, to mitigate the “Keytruda cliff.” While analysts have a mean price target of $127, TIKR’s valuation model suggests a higher fair value of $181.96, contingent on the successful execution of its new pipeline.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.